The First Methadone Advocacy Conference

 

Time:  September 26, 1998 
9:30 AM to 5 PM


Place: Roosevelt Hospital Auditorium

 1000 Tenth Avenue

 between 58-59th Street

 New York City

Topics:  A conference for methadone
patients and by methadone patients.


This important conference gives a voice
to the voiceless. Topics discussed


will be stigma, prejudice, misunderstandings
about methadone, new


regulations, physician prescribing and
the importance for methadone


patients to be involved in “THEIR” treatment.

Sponsors: National Alliance of Methadone
Advocates (NAMA)


            
Methadone A Legitimate Treatment Alternative (MALTA)

Cost: $25.00 or Methadone Patient ID
Card and/or Donation

Contact: Joycelyn Woods

  212-595-NAMA

  [email protected]

Pre-registration is recommended
to insure adequate seating.

Back
to News

 

Similar Posts

  • NAMA SITE SEARCH

    Admin 04/08/2022

    Search the NAMA site with Digital Equipment Corporation’s excellent ALTAVISTA search engine! Just type your search term(s) next to the text Reading “url:Methadone.org” Search for:    NOTE: This search takes you away from our site. Either use your browser’s “Back” button or choose one of the results returned by AltaVista to continue with us.  

  • Myths About Methadone by Emmett Velten

    Admin 10/21/2021

    Not just in substance abuse, mental health, and AIDS services do methadone patients face routine discrimination.  San Francisco MUNI will not allow methadone patients to drive its buses, even though an important legal ruling in New York overturned a similar policy (Beazer vs New York City Transit Authority, 1975). Not just in those instances but…

  • |

    Page 4098 Federal Register

    Admin 08/28/2021

     Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations (i)                 Unsupervised or take-home use.   To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.   (1)   Any patient…